企業プロフィール
Cingulate Inc. 株価・ニュース・カタリスト
- ティッカー:
- CING
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
5.21 USD (+2.36%)
終値
最終更新: 2026年8月17日
54.3M USD
時価総額
株価変動の要因
As of Aug 17, 2026, CING closed up 2.36% at $5.21. No new same-company headline was identified in the current news window.
企業概要
Precision Timed Release Platform
Cingulate develops next-generation medicines using its Precision Timed Release platform. The technology uses multi-core tablets to deliver several precisely timed drug releases during the day, with the goal of extending therapeutic coverage and improving adherence.
CTx-1301 ADHD Candidate
CTx-1301 is a once-daily, multi-core dexmethylphenidate hydrochloride tablet for attention-deficit/hyperactivity disorder. It is designed to provide rapid onset and efficacy throughout the active day and is being reviewed through the FDA’s 505(b)(2) pathway.
505(b)(2) Development Model
The regulatory strategy uses an established active pharmaceutical ingredient while seeking approval for a differentiated release profile and dosage form. This allows Cingulate to focus development on pharmacokinetics, duration of effect, manufacturing, and product-specific clinical performance.
Commercial Readiness
Cingulate is preparing payer access, distribution, supply chain, artificial intelligence-supported marketing technology, commercial manufacturing, and a sales organization for CTx-1301. Launch remains dependent on FDA approval.
今後のカタリスト
- Resubmission of the CTx-1301 NDA after completion of the requested manufacturing and CMC work.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。